Droxidopa is a synthetic amino acid precursor that acts as a prodrug of norepinephrine, indicated for the treatment of symptomatic neurogenic orthostatic hypotension associated with conditions such as… Read more




![Chemical structure of (2S,3R)-2-Amino-3-(benzo[d][1,3]dioxol-5-yl)-3-hydroxypropanoic Acid](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F88375-62-6-2S3R-2-Amino-3-benzod13dioxol-5-yl-3-hydroxypropanoic-Acid.png&w=3840&q=75)

![Chemical structure of 2,3,8,9-Tetrahydroxy-11,12-dihydro-5,11-epiminodibenzo[a,e][8]annulene-5(6H)-carboxylic Acid](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F2389-Tetrahydroxy-1112-dihydro-511-epiminodibenzoae8annulene-56H-carboxylic-Acid.png&w=3840&q=75)
![Chemical structure of 2,3,8,9-Tetrahydroxy-11,12-dihydro-5,11-epiminodibenzo[a,e][8]annulene-5(6H)-carboxylic Acid Hydrochloride](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F2389-Tetrahydroxy-1112-dihydro-511-epiminodibenzoae8annulene-56H-carboxylic-Acid-Hydrochloride.png&w=3840&q=75)

![Chemical structure of 2-amino-3-(benzo[d][1,3]dioxol-5-yl)-3-hydroxypropanoic acid](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F56672-56-1-2-amino-3-benzod13dioxol-5-yl-3-hydroxypropanoic-acid.png&w=3840&q=75)




![Chemical structure of 5,6,11,12-Tetrahydro-5,11-epiminodibenzo[a,e][8]annulene-2,3,8,9-tetraol](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F90044-46-5-561112-Tetrahydro-511-epiminodibenzoae8annulene-2389-tetraol.png&w=3840&q=75)






















Droxidopa is a synthetic amino acid precursor that acts as a prodrug of norepinephrine, indicated for the treatment of symptomatic neurogenic orthostatic hypotension associated with conditions such as Parkinson’s disease. This category includes a comprehensive range of high-quality reference standards, including pharmacopeial and non-pharmacopeial impurities, synthesis-related degradation products, and stable isotope-labelled compounds. Pharmaceutical laboratories utilize these materials to support essential activities such as impurity profiling, the validation of analytical methods like HPLC and LC-MS, and rigorous quality control protocols. By providing structurally characterized standards that mimic the drug’s metabolic and degradation pathways, this collection facilitates the accurate identification and quantification of impurities in drug substance and finished products. These tools are indispensable for maintaining regulatory compliance and ensuring that drug development, stability testing, and batch release procedures meet stringent safety and performance standards for this therapeutic agent.